News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Naveen Pemmaraju: The Evolving Landscape of Epigenetic Target Molecules and Therapies in Myeloid Cancers
Naveen Pemmaraju/mdanderson.org
May 18, 2025, 12:23

Naveen Pemmaraju: The Evolving Landscape of Epigenetic Target Molecules and Therapies in Myeloid Cancers

Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a post on X about a paper he co-authuored with colleagues published in Leukemia:

“Delighted to share our brand new review article led by Florian Heidel. The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on AML and MPN.”

Title: The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms

Authors: Michael Kühn, Naveen Pemmaraju, Florian Heidel.

Naveen Pemmaraju: The Evolving Landscape of Epigenetic Target Molecules and Therapies in Myeloid Cancers

You can read the Full Article in Leukemia.

More posts featuring Naveen Pemmaraju.

AML cancer epigenetic target molecules Florian Heidel Leukemia Michael Kühn MPN Myeloid cancers Naveen Pemmaraju OncoDaily Oncology
Special Coverage
Science
May 18, 2025, 12:23
Naveen Pemmaraju: The Evolving Landscape of Epigenetic Target Molecules and Therapies in Myeloid Cancers
Career
May 18, 2025, 12:13
Narjust Florez Has Been Named 2025 Rising Star Woman in Healthcare by Leaders in Healthcare
Blog
May 18, 2025, 11:58
Zacharoula Sidiropoulou Calls for Global Investment in Access to Cancer Surgery in LMICs
Blog
May 18, 2025, 11:49
How Cancer Treatment Has Transformed with Modern Therapies - FDA Oncology
Blog
May 18, 2025, 11:43
Goutham Sunny: Immunotherapy in MSI-H Gastric Cancer - NO LIMIT trial
Blog
May 18, 2025, 11:32
Jeff Yang: Excited to be with Our Amazing ALCSI and MGH Teams at the Joseph R. Betancourt Health Fair
Blog
May 18, 2025, 11:31
Heber Reyes: Inspiring Experts Discuss Lung Cancer, Gender Equity, and Biomarker Testing
Blog
May 18, 2025, 11:29
FDA Commissioner Martin Makary Hosted Kyle Diamantas and Sanjula Jain-Nagpal on FDA Direct Podcast Episode 2
Opinion
May 18, 2025, 11:28
Mark Lawler: Honored to Present the Irrefutable Evidence to Westminster Health Forum
Blog
May 18, 2025, 11:13
Talha Badar: Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress
Blog
May 18, 2025, 11:12
Pablo Mando: Honored and Privileged to Have Been Part of the Faculty of BCY at ESMO Breast 2025
Science
May 18, 2025, 10:59
Nina Niu Sanford: FOLFIRINOX vs. Single Agent Gemcitabine in Locally Advanced Pancreas Cancer